Immune checkpoint inhibitors (ICIs), particularly inhibitors targeting programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4), have shown promising therapeutic potential for patients with locally advanced rectal cancer (LARC) and metastatic CRC (2, 3). The gene discussed is CTLA4; the disease is rectal cancer.